Ratings Edwards Lifesciences Corporation Borsa Italiana

Equities

4EW

US28176E1082

End-of-day quote Borsa Italiana Other stock markets 23:00:00 06/05/2024 BST			5-day change	1st Jan Change
79.67 ^EUR	+0.67%		-0.14%	+14.50%

05-09	Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability	CI
05-07	Barclays Adjusts Edwards Lifesciences Price Target to $101 From $100	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
EDWARDS LIFESCIENCES CORPORATION	+14.50%	51.28B	-
THERMO FISHER SCIENTIFIC	+8.88%	219B	B
DANAHER CORPORATION	+8.68%	185B	B-
INTUITIVE SURGICAL, INC.	+14.25%	135B	B-
BOSTON SCIENTIFIC CORPORATION	+28.18%	107B	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.48%	51.01B	B+
AGILENT TECHNOLOGIES, INC.	+4.39%	41.85B	A
GE HEALTHCARE TECHNOLOGIES INC.	+7.00%	37.02B	-
RESMED, INC.	+26.06%	31.27B	B+
PHILIPS NV	+16.53%	23.66B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes